

Amendments to the Claims:

This listing of claims replaces any and all prior claim lists.

Listing of Claims:

Claim 1 (original). A nucleic acid comprising one sequence selected from the group consisting of nucleic acid sequences set forth in SEQ ID NO:1 to SEQ ID NO:174 in the Sequence Listing.

Claim 2 (original). The nucleic acid according to claim 1, comprising one sequence selected from the group consisting of nucleic acid sequences set forth in SEQ ID NO:1 to SEQ ID NO:14 in the Sequence Listing.

Claim 3 (currently amended). A nucleic acid complementary to the nucleic acid according to claim 1 ~~or 2~~.

Claim 4 (currently amended). A nucleic acid capable of hybridizing to the nucleic acid according to ~~any of claim 1-3~~ claim 1 under stringent conditions.

Claim 5 (original). A nucleic acid probe comprising nucleic acid (a) or nucleic acid (b):

(a) a nucleic acid comprising a partial length or the full length of one sequence selected from the group consisting of nucleic acid sequences set forth in SEQ ID NO:1 to SEQ ID NO:174 in the Sequence Listing, or a nucleic acid complementary thereto;

(b) a nucleic acid capable of hybridizing under stringent conditions to a nucleic acid comprising a partial length or the full length of one sequence selected from the group

consisting of nucleic acid sequences set forth in SEQ ID NO:1 to SEQ ID NO:174 in the Sequence Listing, or a nucleic acid complementary thereto.

Claim 6 (original). The nucleic acid probe according to claim 5, comprising nucleic acid (a) or nucleic acid (b):

(a) a nucleic acid comprising a partial length or the full length of one sequence selected from the group consisting of nucleic acid sequences set forth in SEQ ID NO:1 to SEQ ID NO:14 in the Sequence Listing, or a nucleic acid complementary thereto;

(b) a nucleic acid capable of hybridizing under stringent conditions to a nucleic acid comprising a partial length or the full length of one sequence selected from the group consisting of nucleic acid sequences set forth in SEQ ID NO:1 to SEQ ID NO:14 in the Sequence Listing, or a nucleic acid complementary thereto.

Claim 7 (currently amended). A diagnostic agent for stage 4s neuroblastoma comprising the nucleic acid probe according to claim 5 or 6 as the active ingredient.

Claim 8 (original). A primer containing DNA (a) or DNA (b):

(a) a DNA comprising one sequence selected from the group consisting of nucleic acid sequences set forth in SEQ ID NO:175 to SEQ ID NO:1076 in the Sequence Listing, or a DNA complementary thereto;

(b) a DNA capable of hybridizing under stringent conditions to the DNA comprising one sequence selected from the group consisting of nucleic acid sequences set forth in SEQ ID NO:175 to SEQ ID NO:1076 in the Sequence Listing, or a DNA complementary thereto.

Claim 9 (original). A primer containing DNA (a) or DNA (b):

(a) a DNA comprising one sequence selected from the group consisting of nucleic acid sequences set forth in SEQ ID NO:175 to SEQ ID NO:202 and SEQ ID NO:519 to SEQ ID NO:540 in the Sequence Listing, or a DNA complementary thereto, or a DNA comprising one sequence selected from the group consisting of nucleic acid sequences set forth in SEQ ID NO:785 to SEQ ID NO:798 in the Sequence Listing, or a DNA complementary thereto;

(b) a DNA capable of hybridizing under stringent conditions to the DNA comprising one sequence selected from the group consisting of nucleic acid sequences set forth in SEQ ID NO:175 to SEQ ID NO:202 and SEQ ID NO:519 to SEQ ID NO:540 in the Sequence Listing or a DNA comprising one sequence selected from the group consisting of nucleic acid sequences set forth in SEQ ID NO:785 to SEQ ID NO:798 in the Sequence Listing, or a DNA complementary thereto.

Claim 10 (currently amended). A diagnostic kit for stage 4s neuroblastoma comprising one pair of the primers according to claim 8 or 9 as the active component.

Claim 11 (original). A method for determining stage 4s neuroblastoma, the method comprising detecting the presence or absence of a nucleic acid comprising one sequence selected from the group consisting of nucleic acid sequences set forth in SEQ ID NO:1 to SEQ ID NO:14 in the Sequence Listing from a clinical tissue sample of neuroblastoma.

Claim 12 (original). A nucleic acid microarray comprising a solid phase support and a combination of plural nucleic acids each comprising a partial length- or the full length-nucleic acid comprising a nucleic acid sequence set forth in one of SEQ ID NO:1 to SEQ ID NO:174 in the Sequence Listing immobilized on the solid phase support.

Claim 13 (original). A nucleic acid microarray comprising a solid phase support and a combination of plural nucleic acids each comprising a nucleic acid sequence set forth in one of SEQ ID NO:175 to SEQ ID NO:200, a nucleic acid sequence set forth in one of SEQ ID NO:519 to SEQ ID NO:540 or a nucleic acid sequence set forth in one of SEQ ID NO:785 to SEQ ID NO:798 immobilized on the solid phase support.

Claim 14 (new). A nucleic acid capable of hybridizing to the nucleic acid according to any of claim 3 under stringent conditions.

Claim 15 (new). A diagnostic kit for stage 4s neuroblastoma comprising one pair of the primers according to claim 9 as the active component.

Claim 16 (new): The nucleic acid according to claim 1, wherein said nucleic acid comprises a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:38, SEQ ID NO:124, SEQ ID NO:156, SEQ ID NO:191, and SEQ ID NO:192 in the Sequence Listing.